MedCity News

APRIL 20, 2023

A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024. Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer.

Leads 105

Leads Biopharma Pharma 105

PM360

SEPTEMBER 18, 2024

Varady has spent the last 20 years leading integrated marketing campaigns for biotech and healthcare companies in both U.S. His experience leading large-scale agency accounts for top 10 biopharma companies has led to the successful commercialization of products across a wide array of therapeutic categories. Conshohocken, Pa.,

Marketing 52

Marketing Media Healthcare Healthcare 52

PM360

SEPTEMBER 17, 2024

17, 2024 – FINN Partners, one of the world’s leading independent marketing and communications agencies, today announces the appointment of Julie Adrian as Managing Partner and UK Health Group Lead. In the newly created position, Adrian reports to Gil Bashe, Chair FINN Global Health and Purpose.

Leads 52

Leads Management Marketing Biopharma 52

Clarivate

SEPTEMBER 11, 2024

Though there is no cure for the disease, people with Alzheimer’s can receive personalized, multimodal care and support to delay deterioration of their functional status and quality of life and alleviate the burden imposed on their care partners (Emblad, 2021; Bayly, 2021; Xiang, 2024). Food and Drug Administration, 2023 and 2024).

Food and Drug Administration 59

Food and Drug Administration Pharmacology Food FDA 59

pharmaphorum

SEPTEMBER 6, 2022

Pleco Therapeutics has closed a first-round financing, raising just over €17 million that it says will fund the development of its lead therapy for acute myeloid leukaemia (AML) through to regulatory filings in the US and EU. million in equity and R&D funding from Belgian biopharma company Hyloris, which was first announced last year.

Leads 98

Leads Biopharma Government Patients 98

PM360

DECEMBER 20, 2023

With 2024 on the horizon, many in the biopharma space are taking stock of 2023 and what the current environment means for their potential success next year. Evaluate’s VC data show quarter-over-quarter drops in the number of biopharma companies raising private cash and in the amount of money raised.

Biopharma 111

Biopharma Pharma Marketing Management 111

pharmaphorum

JANUARY 9, 2023

Biopharma and healthcare group Chiesi Farmaceutici S.p.A. Supported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 is to acquire the 2015-established Amryt Pharma Plc. on 6 th January.

Pharma 97

Pharma Biopharma Management Medicine 97

PM360

SEPTEMBER 30, 2024

The 2024 Sparkle of Hope event will be on November 14 at 5:30pm in Pompton Plains, NJ. He says it was founded on the belief that many gaps in mental health support, and especially support for veterans, could be mitigated by the involvement of biopharmaceutical companies.

Biopharma 52

Biopharma Patients Marketing Healthcare 52

European Pharmaceutical Review

MARCH 7, 2024

Last month, construction began on Europe’s first industrial-scale facility dedicated to the production of lead-212 based radioligand therapies. The Phase II clinical trial for Orano Med’s candidate AlphaMedix ( 212 Pb-DOTAMTATE) is still ongoing and top-line data are expected in mid-2024.

Manufacturing 52

Manufacturing Food and Drug Administration Marketing Management 52

Clarivate

MAY 14, 2024

While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7

Manufacturing 52

Manufacturing Marketing Leads Medicine 52

Pharmaceutical Technology

APRIL 4, 2023

While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. The Boston, Massachusetts-based Scorpion expects to submit an investigational new drug (IND) application for STX-721 to the US Food and Drug Administration (FDA) in mid-2023, with an IND application for STX-241 expected in H1 2024. Up to 12.5%

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Clarivate

SEPTEMBER 5, 2024

This blog summarizes a portion of the data collected, which was previously shared in a poster presented at the May 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference (Read the poster ).

Insurance 52

Insurance Marketing Manufacturing Prescription 52

PM360

APRIL 22, 2024

With an ever- increasing demand for their time and attention, it is more difficult than ever for biopharma representatives to convey their message to the physician audience. In one survey, only 12% of HCPs said they felt biopharma companies are very effective at providing HCP education and training to them.

Education 59

Education Physicians Healthcare Healthcare 59

PM360

JUNE 24, 2024

This fuels an enormous need for effective patient communication and education as new therapies move through the biopharma pipeline. Those of us in the biopharma industry know how fraught drug development can be. As the saying goes, they are individually rare but collectively common. Many people, cumulatively, are affected.

Marketing 52

Marketing Patients Food and Drug Administration Digital Media 52

PM360

AUGUST 26, 2024

Q: In a May 2024 interview with MIT President Sally Kornbluth; Sam Altman, OpenAI’s CEO, recently shared how he believes that AI’s technology is potentially “the biggest, the best, and the most important” of the technology revolutions. Adaptability leads to survival, as Darwin showed us, over strength or intellect.

Distribution 52

Distribution Biopharma Healthcare Healthcare 52

Clarivate

JUNE 21, 2024

The lack of transparency and interpretability in how algorithmic decisions are made could lead to concerns regarding the reproducibility and trustworthiness of review results. However, we are also deliberately adopting a cautious approach (Cochrane, 2024).” References Cochrane, 2024. Available: [link] [Accessed 17/06/2024].

Training 81

Training Government Medical science Ethics 81

PM360

SEPTEMBER 30, 2024

In late 2023, Deloitte found that over half of 105 surveyed global biopharma leaders were committed to reducing environmental impact and advancing sustainability by minimizing water use, sourcing sustainable materials, and overhauling supply chains.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

European Pharmaceutical Review

OCTOBER 8, 2024

CPHI Milan, the premier international pharmaceutical event, will be held from 8 to 10 October 2024 at Fiera Milano, Italy. However, the venture capital branches of leading pharmaceutical firms are proving to be innovation engines, vital in fostering advances and addressing key healthcare issues.

Pharma 52

Pharma Manufacturing Pharmaceutical Management 52

European Pharmaceutical Review

NOVEMBER 30, 2023

Licensing of the manufacturing suites is expected in early 2024. NEWS: Biopharma struggling to find talent with adequate digital skills Looking onward to 2028, the Skills report predicted that, out of a total 81 percent within the cell and gene therapy industry, roles will span support services, R&D and discovery, and bioprocessing.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

Zymewire

FEBRUARY 8, 2024

Skip to a topic Axonis' journey and purpose The impact of the economic client on emerging biopharma The place of Artificial Intelligence in drug development & discovery Working with NASA Relationships with CROs, CDMOs, and other service providers What made you want to start Axonis? sending neurons to space.

Competition 52

Competition Leads Patients Marketing 52

Clarivate

OCTOBER 30, 2022

Of surveyed MCOs that cover or plan to cover DTx apps for the three conditions, more than 80% of respondents reported reimbursing DTx for at least one of the conditions in their fully insured commercial plans as of March 2022, with the remainder expecting to do so by 2024. Payers also noted some coverage in their Medicare and Medicaid plans.

Insurance 52

Insurance FDA Marketing Prescription 52

Clarivate

DECEMBER 19, 2022

The plans are profitable and continue to draw new Medicare enrollees, leading all top payers to make investments in retaining and attracting enrollees. Expansion opportunities for 2024 are relatively obvious, since the partners could expand to the three states with Walmart Health locations (Arkansas, Illinois, Texas ).

Competition 52

Competition Retail Insurance Marketing 52

European Pharmaceutical Review

APRIL 30, 2024

What are the top three trends that you are seeing in the biopharma manufacturing space? Let’s talk about continuous biopharma manufacturing. Speaking of your biopharma clients, what are you hearing about their main priorities? Sticking to the cell and gene therapy space, what’s your main prediction for 2024?

Manufacturing 97

Manufacturing Food and Drug Administration Biopharma Marketing 97

Clarivate

AUGUST 7, 2024

The three largest pharmacy benefit managers (PBMs) in the United States—Express Scripts, OptumRx and CVS Caremark—control more than 80% of the market share (per Clarivate data, as of January 2024). The pricing estimates are not guaranteed, leading to potential unexpected expenses.

Retail 59

Retail Marketing Competition Biopharma 59

Clarivate

MAY 13, 2024

According to Clarivate’s latest enrollment data, as of January 2024, Medicaid enrollment had plummeted by nearly 9 million compared to six months prior. For 2024, 18% of enrollees were new to exchange coverage, according to the Centers for Medicare and Medicaid Services. million between January 2023 and January 2024. to about 2.5

Insurance 52

Insurance Marketing Healthcare Healthcare 52

Clarivate

DECEMBER 6, 2022

The IDN also plans to open a proton beam therapy center by 2024, which will be the first in Wisconsin. Bill Melville, Lead Healthcare Research Analyst. For more on the forces driving IDNs, please view our recent webinar on IDN and provider trends.

Networking 52

Networking Healthcare Healthcare Competition 52

European Pharmaceutical Review

SEPTEMBER 2, 2024

The oral treatment GMRx2 is biopharma George Medicines’ lead drug candidate. As well as the findings being presented at the European Society of Cardiology Congress (ESCC) 2024, the study was published in JAMA. The once-daily, three-in-one pill contains telmisartan, amlodipine and indapamide at a quarter, half or standard doses.

Food and Drug Administration 59

Food and Drug Administration Medicine Biopharma Food 59

PM360

OCTOBER 18, 2024

And it is already leading us as an industry to make medicines differently. v=M25xiFblCbE ) JPM 2024: FogPharma’s new CEO, Mathai Mammen, unveils ‘contrarian.’ a company he co-founded from graduate school based on his work at Harvard University with Dr. George Whitesides, which split to form Theravance Biopharma and Innoviva.

Medicine 52

Medicine Education Prospecting Networking 52

PM360

AUGUST 7, 2024

Ari Wexler Group Senior Vice President, Engagement Strategy CMI Media Group awexler@cmimediagroup.com Historically, the pharmaceutical marketing industry has relied on leading performance KPIs, such as likes, shares, and clicks to measure a campaign’s success against brand goals.

Media 52

Media Education Physicians Marketing 52

PM360

OCTOBER 22, 2024

DANNY SIGURDSON CEO and Founder Courier Health To effectively engage patients and prescribers to improve overall adherence to prescribed medication regimens, biopharma companies first need the visibility and full context of where a patient stands in their treatment journey. The axiom “you can’t manage what you can’t measure” applies here.

Education 52

Education Side effects Medical Patients 52

Pharmaceutical Technology

JANUARY 25, 2023

In December 2022, AEON Biopharma, a biopharmaceutical company, announced its plans to go public through a merger with the SPAC Priveterra Acquisition Corp. While the stock market indices may be down by 40%, the market cap of some companies is down by 90%, leading to news of restructurings and closures, says Ryan.

Marketing 69

Marketing Biopharma Pharma Competition 69

Clarivate

DECEMBER 14, 2023

Pharmaceutical benefit managers, M&A activity among integrated delivery networks, disruption by nontraditional healthcare entities, enrollment, and the 2024 presidential election are five areas to pay attention to moving into 2024. Clarivate experts explain why these topics are ones to watch in 2024.

Marketing 52

Marketing Healthcare Healthcare Insurance 52

Clarivate

OCTOBER 17, 2024

Congressional Democrats introduced legislation to make the subsidies permanent in September 2024, but the legislation has no chance of passage so close to the election. 31, 2024, and providers and payers are pushing for an extension. 31, 2024, and providers and payers are pushing for an extension. As of Aug.

Healthcare 52

Healthcare Healthcare Government Insurance 52